Off Brand versions of the Weight loss drugs Ozempic and Wegovy under FDA watch

The U.S. Food and Drug Administration is cautioning consumers about safety issues related to the increasing usage of weight loss drugs such as Ozempic and Wegovy. 

The use of generic versions of these medications could be hazardous, according to federal regulators. As a result, many individuals have sought lower-cost semaglutide doses, which is the active ingredient in both Ozempic and Wegovy, from compound pharmacies.

By Anita Johnson-Brown

More News from Los Angeles

• News Mix Top News
• Anita Brown's commentary Opinions matter